Advertisement
U.S. Markets closed

Indaptus Therapeutics, Inc. (INDP)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Visitors trend2W10W9M
1.4700-0.0200 (-1.34%)
At close: 04:00PM EDT
1.4700 0.00 (0.00%)
After hours: 07:15PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.4900
Open1.5100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4122 - 1.4700
52 Week Range1.0300 - 3.2500
Volume4,124
Avg. Volume17,434
Market Cap14.989M
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-1.8600
Earnings DateAug 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

    NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, provides an update regarding key clinical advancements in its Phase 1 trial of lead drug candidate Decoy20. The Safety Review Committee examined weekly administration data at the lower Decoy20 dose and cleared unrestricted enrollment of patients at this dose. The safet

  • GlobeNewswire

    Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy

    NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that its Founder and Chief Scientific Officer, Dr. Michael Newman, will participate as a panelist in an upcoming webinar hosted by Lumanity. The webinar, titled "Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as a 'Next Big Thing' in Cancer Immunotherapy

  • GlobeNewswire

    Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

    NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024. Event: Fireside Chat at 2024 Maxim Healthcare Virtual SummitDate: Wednesday, October 16, 2024Time: 11:00